1. FRI0193 SC vs IV abatacept in RA: post-hoc efficacy analysis of long-term acquire (SC) data with aim (IV) data. (23rd January 2014) Authors: Genovese, M.; Pacheco Tena, C.; Covarrubias Cobos, A.; Leon, G.; Mysler, E.F.; Keiserman, M.; Valente, R.; Nash, P.; Simon Campos, J.A.; Box, J.; Legerton, C.W.; Nasonov, E.; Durez, P.; Delaet, I.; Elegbe, A.; Alten, R. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 378 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. FRI0227 Five-Year Safety and Efficacy of Subcutaneous Abatacept in Patients with Moderate To Severely Active RA and An Inadequate Response To MTX: Long-Term Extension of The Phase III, Double-Blind, Randomized Acquire Study. (15th July 2016) Authors: Genovese, M.C.; Pacheco Tena, C.; Covarrubias, A.; Leon, G.; Mysler, E.; Keiserman, M.; Valente, R.; Nash, P.; Simon-Campos, J.A.; Box, J.; Legerton, C.W.; Nasonov, E.; Durez, P.; Elegbe, A.; Wong, R.; Li, X.; Banerjee, S.; Alten, R. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 515 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. SAT0396 Secukinumab Provides Sustained Improvements in The Signs and Symptoms of Active Ankylosing Spondylitis: 2-Year Results from A Phase 3 Trial with Subcutaneous Loading and Maintenance Dosing (Measure 2). (15th July 2016) Authors: Marzo-Ortega, H.; Legerton, C.W.; Sieper, J.; Kivitz, A.; Blanco, R.; Cohen, M.; Zuazo, J.; Readie, A.; Porter, B.; Richards, H. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 812 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗